Press Detail





Biotest AG: Biotest AG successfully completes capital increase 2013: New shares were oversubscribed, Issuing volume amounts to EUR 76 million


Biotest AG / Key word(s): Capital Increase

26.06.2013 / 12:30


/
PRESS RELEASE

Biotest AG successfully completes capital increase 2013: New shares were oversubscribed, Issuing volume amounts to EUR 76 million

Dreieich, June 26, 2013 - During this year's annual shareholders meeting of Biotest AG, chief executive officer Professor Dr. Gregor Schulz announced a capital increase to finance the company's expansion strategy. Today Biotest announces the successful completion of the capital increase: the maximum amount of 1,461,909 new preference shares at a price of EUR 52 per share were acquired by shareholders exercising their subscription rights or were placed with institutional investors due to high interest in the share. Thus the gross proceeds of the issue amount to EUR 76 million.

Following a roadshow where the management presented reasons for the capital increase as well as the capacity expansion to potential investors, equinet Bank - as early as June 10 and within just a few hours - sold all 1,461,909 new preference shares as pre-placements to institutional investors. The placement was in part subject to claw-back rights of the company's shareholders. This procedure was possible because OGEL GmbH and Kreissparkasse Biberach/special funds of Kreissparkasse Biberach declared that they will not exercise their subscription rights, resulting in approx. 598,000 preference shares being placed without claw-back. Of the remaining approx. 864,000 shares, Biotest shareholders acquired approx. 52 % of the shares exercising their subscription rights and approx. 413,000 new preference shares placed, which were subject to claw-back and for which subscription rights were not exercised, will be delivered to the institutional investors.

Thus 1,461,909 bearer preference shares without nominal value (no-par shares) with a notional interest of EUR 2.56 per share were issued. Biotest's board of management and supervisory board took all decisions necessary under the German Stock Corporation Act and filed for registration of the capital increase with the commercial register.

The stock exchange registration of the new preference shares will presumably take place on June 28, 2013 and their delivery on July 1, 2013. The company will then receive the proceeds of the share issue amounting to EUR 76 million.

Biotest Aktiengesellschaft
The Management Board
Biotest AG
Landsteinerstr. 5
63303 Dreieich
www.biotest.de

ISIN: DE0005227235; DE0005227201
WKN: 522723; 522720

This publication constitutes neither an offer to sell nor a solicitation to buy or subscribe to securities.

The information contained herein is not for distribution, directly or indirectly, in or into the United States of America and must not be distributed to U.S. persons (as defined in Regulation S of the U.S. Securities Act of 1933, as amended ('Securities Act')) or publications with a general circulation in the United States of America. This publication constitutes neither an offer to sell nor a solicitation to buy or subscribe to securities in the United States of America. The securities have not been and will not be registered under the Securities Act and may not be offered or sold in the United States of America absent registration or an exemption from registration under the Securities Act. The Issuer does not intend to register any portion of the offering in the United States of America or to conduct a public offering of the securities in the United States of America.

This publication is only addressed to and directed at persons in member states of the European Economic Area who are 'qualified investors' within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC as amended) ('Qualified Investors'). In addition, in the United Kingdom, this publication is being distributed only to, and is directed only at, Qualified Investors who (i) are persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the 'Order'), (ii) are high net worth entities falling within Articles 49(a) to (d) of the Order, or (iii) other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as 'relevant persons'). Any investment or investment activity to which this publication relates is only available to and will only be engaged in with (i) in the United Kingdom, relevant persons, and (ii) in any member state of the European Economic Area other than the United Kingdom, Qualified Investors. Any other persons who receive this publication in the European Economic Area should not rely on or act upon it.

The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States of America, Canada, Japan or Australia.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has about 1.800 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart

 



End of Corporate News


26.06.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.medientreff.de and www.dgap.de



218187  26.06.2013